1. 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. (31st December 2020) Authors: Teichner, Paula; Wu, Sterling; Zhang, Feifan; Dorey, David; D'Amico, Ronald; Griffith, Sandy; Sutton, Kenneth; McCoig, Cynthia C; Upadhyay, Ojesh R; Polli, Joseph; Margolis, David; Van Solingen-Ristea, Rodica; Vandermeulen, Kati; Spreen, William; Patel, Parul Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes. (4th December 2021) Authors: Taiwo, Babafemi O; Tan, Darrell; Patel, Parul; Teichner, Paula; Polli, Joseph; Garside, Louise; D'Amico, Ronald; Talarico, Christine L; Van Solingen-Ristea, Rodica; Baugh, Bryan; Spreen, William; Aboud, Michael; Bosse, Matthew Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗